花旗:阿里健康(0241.HK)明年純利增速有望達30% 呼籲買入
花旗研報指,阿里健康(0241.HK)在收購阿里巴巴(9988.HK)旗下的Ali JK ZNS後,將成為阿里巴巴旗下唯一的醫療旗艦平台。維持阿里健康"買入"及首選評級,目標價14港元。預期,若新收購業務在未來三年實現按年30%收入及25%淨利潤增長,阿里健康2021及2022年的淨利潤增速分別可達30%及10%。該行相信,當收購完成後,阿里健康將成為中國線上處方藥銷售逐漸放開和加速滲透的主要受益者。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.